Yes, bile acid diarrhea (BAD) can absolutely occur in patients with an intact gallbladder.
BAD is not limited to post-cholecystectomy patients—in fact, the majority of BAD cases occur in patients with intact gallbladders, particularly those with idiopathic (primary) BAD, which represents a distinct pathophysiologic entity. 1
Understanding BAD Classification
BAD is traditionally classified into three types:
- Type 1 (Secondary BAD): Results from ileal disease or resection (e.g., Crohn's disease, ileal resection)
- Type 2 (Primary/Idiopathic BAD): Occurs without identifiable structural cause—this is the most common form in patients with intact gallbladders
- Type 3 (Post-cholecystectomy BAD): Develops after gallbladder removal
The key point: Type 2 (primary) BAD affects patients with intact gallbladders and accounts for approximately 25-50% of patients diagnosed with diarrhea-predominant IBS (IBS-D) or functional diarrhea. 2, 3
Pathophysiology in Intact Gallbladder Patients
In primary BAD with an intact gallbladder, the mechanism involves:
- Defective FGF19 (fibroblast growth factor 19) production: This hormone normally provides feedback inhibition of hepatic bile acid synthesis. When deficient, excessive bile acids are produced 4, 5
- Impaired enterohepatic circulation: Despite having a gallbladder, the ileal reabsorption mechanism fails
- Genetic variations: Affecting proteins involved in bile acid transport and metabolism 3
The gallbladder's presence does not prevent this dysregulation—the problem lies in the ileal-hepatic feedback loop, not gallbladder storage capacity.
Prevalence Data
BAD is remarkably common in chronic diarrhea patients with intact gallbladders:
- 28.1% of patients with chronic diarrhea have BAD 2, 6
- Approximately 1-2% of the general population has BAD 7
- One-third of IBS-D cases are actually undiagnosed BAD 7
Clinical Recognition
The Canadian Association of Gastroenterology guidelines specifically identify risk factors beyond cholecystectomy 1:
- Terminal ileal resection
- Abdominal radiotherapy
- Importantly, the absence of these risk factors does not exclude BAD
The guidelines explicitly recommend against using symptom presentation alone to identify BAD, as symptoms are non-specific and overlap significantly with IBS-D 1.
Diagnostic Approach for Intact Gallbladder Patients
For patients with chronic non-bloody diarrhea and normal colonoscopy/biopsies, consider BAD testing regardless of gallbladder status 1:
- SeHCAT testing (if available—not in the US): Conditional recommendation for IBS-D and functional diarrhea 1
- Serum C4 assay: Reflects hepatic bile acid synthesis; specificity of 83% 2
- Serum FGF19: Low levels indicate increased bile acid wasting; specificity of 78% 2
- 48-hour fecal bile acid measurement: Traditional gold standard in the US 2
- Single random stool bile acid measurement: Emerging as practical point-of-care test when combined with fasting serum C4 4
Critical Caveat
The guidelines suggest against empiric bile acid sequestrant trials over diagnostic testing 1, though in clinical practice, a therapeutic trial with cholestyramine remains widely used when diagnostic tests are unavailable. A 6-month clinical response to cholestyramine can confirm the diagnosis 6.
Treatment Confirmation
If a patient with an intact gallbladder responds to bile acid sequestrants (cholestyramine, colesevelam), this strongly supports the diagnosis of primary BAD, regardless of gallbladder status 1, 4.
Bottom line: The presence of a gallbladder does not protect against BAD, and primary (idiopathic) BAD is actually the most common form encountered in gastroenterology practice, affecting patients with structurally normal gastrointestinal tracts including intact gallbladders.